

Andrew Haydon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4612932/andrew-haydon-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

4,306
citations

24
h-index

65
g-index

70
ext. papers

5,918
ext. citations

9.2
avg. IF

4.83
L-index

#	Paper	IF	Citations
65	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	4.0	18
64	Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial.. <i>Cancer Prevention Research</i> , 2022 , OF1-OF11	3.2	1
63	Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial.. <i>Cancer Epidemiology</i> , 2022 , 79, 102173	2.8	
62	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa107	4.6	0
61	383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695 2021 , 9, A417-A417		1
60	341 A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC) 2021 , 9, A367-A367		
59	547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab + RP1 in patients with advanced cutaneous squamous cell carcinoma 2021 , 9, A577-A577		0
58	340 A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC) 2021 , 9, A366-A366		
57	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy 2021 , 9,		4
56	Reply to E. Hindi <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
55	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021 , 7, 744-748	13.4	25
54	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders 2021 , 9,		4
53	Prediagnosis alcohol intake and metachronous cancer risk in cancer survivors: A prospective cohort study. <i>International Journal of Cancer</i> , 2021 , 149, 827	7.5	1
52	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003620	11.6	16
51	Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. <i>Oncologist</i> , 2021 , 26, 461-464	5.7	0
50	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 836-847	21.7	33
49	Factors Explaining Socio-Economic Inequalities in Survival from Colon Cancer: A Causal Mediation Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1807-1815	4	3

48	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021 , 151, 72-83	7.5	2
47	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. <i>Clinical Lung Cancer</i> , 2021 , 22, e425-e430	4.9	4
46	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021 , 124, 574-580	8.7	9
45	The acceleration of ageing in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 343-351	3.6	4
44	Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies. <i>International Journal of Cancer</i> , 2021 , 148, 2759-2773	7.5	0
43	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021 , 91 Suppl 2, 3-13	1	2
42	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' Reply. <i>Lancet Oncology</i> , 2021 , 22, e343-e344	21.7	0
41	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020 , 61, 203-209	1.3	1
40	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 150-156	4	4
39	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2140-2150	2.2	28
38	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 358-365	4.5	21
37	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
36	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma 2020 , 8,		24
35	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020 , 50, 1282-1285	1.6	4
34	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1139-1148	59.2	105
33	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
32	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 701-710	21.7	23
31	Reply to E. Hindle and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1356-1358	2.2	1

30	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <i>BMJ Open</i> , 2019 , 9, e031434	3	7
29	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019 , 6, MMT28	2.1	6
28	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019 , 68, 663-671	19.2	138
27	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 510-520	21.7	123
26	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
25	Concordance of somatic mutational profile in multiple primary melanomas. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 592-603	4.5	1
24	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. <i>International Journal of Surgery</i> , 2018 , 51, 71-75	7.5	4
23	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology, The</i> , 2018 , 19, 562-578	21.7	93
22	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 90-94	2.7	7
21	Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. <i>International Journal of Cancer</i> , 2018 , 142, 238-250	7.5	53
20	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9590-9590	2.2	7
19	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9591-9591	2.2	8
18	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3441-3449	2.2	137
17	Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. <i>British Journal of Cancer</i> , 2018 , 118, 1289-1295	8.7	7
16	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017 , 116, 1558-1563	8.7	72
15	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1813-1823	59.2	778
14	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. <i>British Journal of Cancer</i> , 2017 , 117, 1026-1035	8.7	33
13	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017 , 117, 921-924	8.7	52

12	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017 , 30, 13-27	4.5	30
11	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016 , 8, 346ra92	17.5	688
10	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016 , 16, 339	4.8	11
9	The Victorian Melanoma Service: A 20-year review of an Australian multidisciplinary cancer service. <i>Australasian Journal of Dermatology</i> , 2016 , 57, 235-7	1.3	3
8	Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion. <i>Diseases of the Colon and Rectum</i> , 2016 , 59, 361-8	3.1	17
7	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12 Suppl 7, 5-12	1.9	19
6	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2258-64	2.2	41
5	A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 1014-23	5.7	39
4	Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 507-18	7.4	24
3	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2477-84	2.2	107
2	Investigation of the safety of irreversible electroporation in humans. <i>Journal of Vascular and Interventional Radiology</i> , 2011 , 22, 611-21	2.4	352
1	Inferior vena caval leiomyosarcoma in a patient with past bilateral retinoblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 181-183	1.9	